U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07645924) titled 'A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine' on June 09.
Brief Summary: This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Migraine
Intervention:
DRUG: Elismetrep
Administered orally
DRUG: Placebo
Administered orally
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Kallyope Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....